Physician profile
Jonathan E Helman
NPI 1285161042
$9,635.02
in general payments reported to CMS, 2019-2025
36 companies · $20.05 in 2025
The $20.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,630 · 2022: $1,970 · 2023: $15.06 · 2025: $20.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $4,764.94 | 2021-2022 | |
| Amgen INC. | $767.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $497.50 | 2021-2022 | |
| Abbvie INC. | $486.62 | 2021-2022 | |
| Allergan, INC. | $399.46 | 2021-2022 | |
| Ucb, INC. | $299.97 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $269.81 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $269.46 | 2021-2022 | |
| Genzyme Corporation | $230.62 | 2021-2022 | |
| Sk Life Science, INC. | $225.29 | 2021-2022 | |
| Lilly USA, LLC | $199.18 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $185.15 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $132.00 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $115.94 | 2021 | |
| Sunovion Pharmaceuticals INC. | $99.10 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $80.69 | 2021-2022 | |
| Abbott Laboratories | $60.07 | 2022-2025 | Infinity, Proclaim |
| Jazz Pharmaceuticals INC. | $56.78 | 2021-2022 | |
| Medtronic, INC. | $55.47 | 2022 | |
| Neurelis, INC. | $53.60 | 2021-2022 | |
| Grifols USA, LLC | $39.14 | 2022 | |
| Lundbeck LLC | $34.84 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.90 | 2021 | |
| Grt US Holding, INC. | $31.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.65 | 2022 | |
| Avion Pharmaceuticals | $25.36 | 2022 | |
| Nevro Corp. | $25.04 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.57 | 2021 | |
| Boston Scientific Corporation | $22.36 | 2021 | |
| Almatica Pharma LLC | $22.33 | 2021 | |
| Eisai INC. | $19.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.67 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.54 | 2022 | |
| Emd Serono, INC. | $16.29 | 2021 | |
| Currax Pharmaceuticals LLC | $13.88 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Helman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.